Document is current
Any future updates will be listed below
-
Authors
Hambardzumyan, Karen
Hamsten, Carl
Lourido, Lucía
Saevarsdottir, Saedis
Nilsson, Peter
van Vollenhoven, Ronald F.
Jakobsson, Per-Johan
Idborg, Helena
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 13 March 2025
Accepted: 5 May 2025
First Online: 21 May 2025
Declarations
:
: The SWFOT trial was conducted in accordance with the Declaration of Helsinki and by the regional ethics committees of all participating units [Karolinska Institutet 02-211, Orebro 2002/202 500:16, Umea 2002, Linkoping 02-186, Uppsala Ups 02-241, Goteborg Gbg O 282-01, M 088 − 02, Lund LU 398-01, and Stockholm Central Ethical Review Board (EPN) 2005/1361, 2006/248-3]. All patients provided written informed consent before enrolment in the trial.
: Not applicable.
: R.F.vV. received research support and grants from AbbVie, BMS, GSK, Pfizer, UCB; and Consultancy, honoraria: AbbVie, AstraZeneca, Biotest, BMS, Celgene, GSK, Janssen, Lilly, Novartis, Pfizer, UCB. S.S. is a part-time employee of deCODE genetics unrelated to this work. All the other authors declare that they have no conflicts of interest.
